Judd Moul
Overview:
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009. He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.
Positions:
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Surgery, Urology
School of Medicine
Professor of Surgery
Surgery, Urology
School of Medicine
Professor in Anesthesiology
Anesthesiology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
B.S. 1979
Pennsylvania State University
M.D. 1982
Thomas Jefferson University
Residency, Surgery
Walter Reed Army Medical Center
Residency, Urology
Walter Reed Army Medical Center
Fellowship, Urologic Oncology
Duke University
Grants:
Phase III Randomized Efficacy and Safety Study
Awarded By
Medivation, Inc.
Role
Principal Investigator
Start Date
End Date
A Prospective Observational Cohort Study of Patients with Castration Resistant Prostate Cancer
Administered By
Surgery, Urology
Awarded By
Astellas Pharma Global Development, Inc
Role
Principal Investigator
Start Date
End Date
Exercise Training, Erectile Dysfunction, and Prostate Cancer
Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
IPA - Jens Dannull
Awarded By
Veterans Administration Medical Center
Role
Principal Investigator
Start Date
End Date
IPA Agreement - Jens Dannull
Awarded By
Veterans Administration Medical Center
Role
Principal Investigator
Start Date
End Date
Publications:
Re-thinking how we use prostate health index for African American men
Authors
Kotamarti, S; Morris, K; Moul, JW
MLA Citation
Kotamarti, S., et al. “Re-thinking how we use prostate health index for African American men.” European Urology, vol. 81, 2022, pp. S559–60.
URI
https://scholars.duke.edu/individual/pub1529880
Source
wos-lite
Published In
European Urology
Volume
81
Published Date
Start Page
S559
End Page
S560
Longitudinal outcomes following implementation of baseline PSA risk stratification of men in their forties
Authors
Michael, ZD; Kotamarti, S; Arcot, R; Morris, K; Shah, A; Anderson, J; Armstrong, A; Gupta, R; Preminger, GM; Moul, JW; Oeffinger, K; Shah, K; Polascik, TJ
MLA Citation
Michael, Z. D., et al. “Longitudinal outcomes following implementation of baseline PSA risk stratification of men in their forties.” European Urology, vol. 81, 2022, pp. S567–68.
URI
https://scholars.duke.edu/individual/pub1529881
Source
wos-lite
Published In
European Urology
Volume
81
Published Date
Start Page
S567
End Page
S568
Editorial Commentary
Authors
MLA Citation
Moul, J. W. “Editorial Commentary.” Urology Practice, vol. 8, no. 6, Nov. 2021, p. 674. Scopus, doi:10.1097/UPJ.0000000000000261.01.
URI
https://scholars.duke.edu/individual/pub1526618
Source
scopus
Published In
Urology Practice
Volume
8
Published Date
Start Page
674
DOI
10.1097/UPJ.0000000000000261.01
Molecular Mechanisms of Castrate-Resistant Prostate Cancer.
Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in CRPC have been identified. This focus on understanding the molecular basis of therapeutic resistance, including lineage plasticity, neuroendocrine transformation, and a range of other implicated genomic alterations will hopefully inform decision-making in the care of this lethal cancer.
Authors
MLA Citation
Kotamarti, Srinath, et al. “Molecular Mechanisms of Castrate-Resistant Prostate Cancer.” Urol Clin North Am, vol. 49, no. 4, Nov. 2022, pp. 615–26. Pubmed, doi:10.1016/j.ucl.2022.07.005.
URI
https://scholars.duke.edu/individual/pub1554693
PMID
36309418
Source
pubmed
Published In
Urol Clin North Am
Volume
49
Published Date
Start Page
615
End Page
626
DOI
10.1016/j.ucl.2022.07.005
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review.
BACKGROUND: Urinary microbiota is implicated in many diseases of the urinary tract. The aim of this study was to perform a systematic review of the role of urinary microbiota in prostatic diseases. METHODS: A PubMed/Medline search was undergone from inception through June 2022 for studies investigating urinary microbiota alterations in prostatic diseases, subdivided into benign prostatic hyperplasia (BPH), prostate cancer (PCa), and chronic prostatitis (CP). Study selection followed the PRISMA statement. Phylum, family, genus and species of each bacterium in cancer patients and controls were recorded. Quality of included studies was evaluated using the Critical Appraisal Skills Program (CASP) checklist for non-randomized studies. RESULTS: A total of 16 studies (4 studies on BPH, 9 studies on PCa and 3 studies on CP) comprising 1486 patients were included in our final analysis. Patients with BPH had a different urinary microbial composition, with a certain pattern proven to be associated with a higher lower urinary tract symptoms severity. Regarding PCa, some bacterial phyla/genera/classes/species were more abundant in PCa and others predicted a higher grade disease. In patients with CP, a different microbiota composition and a higher diversity were found, with the symptom severity being influenced mainly by microbiota composition, favoring aerobic microorganisms. CONCLUSION: Urinary microbiota is implicated in prostatic diseases, especially in BPH, PCa and CP. However, given the relative heterogeneity among published studies, this implication suggests better delineation is needed. Further studies are needed to confirm these findings.
Authors
Mjaess, G; Karam, A; Roumeguère, T; Diamand, R; Aoun, F; McVary, K; Moul, JW; De Nunzio, C; Albisinni, S
MLA Citation
Mjaess, Georges, et al. “Urinary microbiota and prostatic diseases: the key for the lock? A systematic review.” Prostate Cancer Prostatic Dis, Oct. 2022. Pubmed, doi:10.1038/s41391-022-00602-w.
URI
https://scholars.duke.edu/individual/pub1553686
PMID
36209236
Source
pubmed
Published In
Prostate Cancer Prostatic Dis
Published Date
DOI
10.1038/s41391-022-00602-w

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Contact:
1573 White Zone, Duke South, Durham, NC 27710
Box 3707 Med Ctr, Durham, NC 27710